{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:58:48Z","timestamp":1785185928198,"version":"3.55.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04516-0","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:01:46Z","timestamp":1784908906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging and targeted therapeutic strategies in colorectal cancer: molecular mechanisms and clinical perspectives"],"prefix":"10.1007","author":[{"given":"Debgopal","family":"Ganguly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-1328","authenticated-orcid":false,"given":"Ananta","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himangshu","family":"Deka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahnabi","family":"Sarmah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhabrota","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousik","family":"Mahanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurjamal","family":"Hoque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyadip","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"4516_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRANON.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol (Elsevier). 2021;14:101174. https:\/\/doi.org\/10.1016\/J.TRANON.2021.101174.","journal-title":"Transl Oncol. (Elsevier)"},{"key":"4516_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5114\/PG.2018.81072","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14:89\u2013103. https:\/\/doi.org\/10.5114\/PG.2018.81072.","journal-title":"Prz Gastroenterol"},{"key":"4516_CR3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.5306\/WJCO.V15.I9.1136","volume":"15","author":"H Fadlallah","year":"2024","unstructured":"Fadlallah H, El MJ, Fakhereddine H, Youssef J, Chemaly C, Doughan S, et al. Colorectal cancer: recent advances in management and treatment. World J Clin Oncol (Baishideng Publishing Group Inc). 2024;15:1136. https:\/\/doi.org\/10.5306\/WJCO.V15.I9.1136.","journal-title":"World J Clin Oncol (Baishideng Publishing Group Inc.)"},{"key":"4516_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/JNCI\/86.6.446","volume":"86","author":"D Abigerges","year":"1994","unstructured":"Abigerges D, Armand JP, Chabot GG, Costa LD, Fadel E, Cote C, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 1994;86:446\u20139. https:\/\/doi.org\/10.1093\/JNCI\/86.6.446.","journal-title":"J Natl Cancer Inst"},{"key":"4516_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS15112620","author":"AS Adebayo","year":"2023","unstructured":"Adebayo AS, Agbaje K, Adesina SK, Olajubutu O. Colorectal cancer: disease process, current treatment options, and future perspectives. Pharmaceutics (Multidisciplinary Digital Publishing Institute (MDPI)). 2023. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15112620.","journal-title":"Pharmaceutics (Multidisciplinary Digital Publishing Institute (MDPI))"},{"key":"4516_CR6","doi-asserted-by":"publisher","first-page":"1356708","DOI":"10.3389\/FPHAR.2024.1356708\/FULL","volume":"15","author":"Y Chai","year":"2024","unstructured":"Chai Y, Liu JL, Zhang S, Li N, Xu DQ, Liu WJ, et al. The effective combination therapies with irinotecan for colorectal cancer. Front Pharmacol (Frontiers Media SA). 2024;15:1356708. https:\/\/doi.org\/10.3389\/FPHAR.2024.1356708\/FULL.","journal-title":"Front Pharmacol (Frontiers Media SA)"},{"key":"4516_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01953-7","author":"Q Li","year":"2024","unstructured":"Li Q, Geng S, Luo H, Wang W, Mo YQ, Luo Q, et al. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Signal Transduct Target Ther (Nature Publishing Group). 2024. https:\/\/doi.org\/10.1038\/s41392-024-01953-7.","journal-title":"Signal Transduct Target Ther (Nature Publishing Group)"},{"key":"4516_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101642","author":"M Aldea","year":"2023","unstructured":"Aldea M, Friboulet L, Apcher S, Jaulin F, Mosele F, Sourisseau T, et al. Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision? ESMO Open (Elsevier BV). 2023. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101642.","journal-title":"ESMO Open (Elsevier B.V.)"},{"key":"4516_CR9","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/cancers14071732","volume":"14","author":"MS Hossain","year":"2022","unstructured":"Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel) MDPI. 2022;14:1732. https:\/\/doi.org\/10.3390\/cancers14071732.","journal-title":"Cancers (Basel) MDPI"},{"key":"4516_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.gie.2021.09.039","volume":"95","author":"RD Dolan","year":"2022","unstructured":"Dolan RD, Bazarbashi AN, McCarty TR, Thompson CC, Aihara H. Endoscopic full-thickness resection of colorectal lesions: a systematic review and meta-analysis. Gastrointest Endosc (Elsevier Inc). 2022;95:216\u201324. https:\/\/doi.org\/10.1016\/j.gie.2021.09.039.","journal-title":"Gastrointest Endosc (Elsevier Inc)"},{"key":"4516_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ng.3488","volume":"48","author":"CC Oakes","year":"2016","unstructured":"Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet (Nature Publishing Group). 2016;48:253\u201364. https:\/\/doi.org\/10.1038\/ng.3488.","journal-title":"Nat Genet (Nature Publishing Group)"},{"key":"4516_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/15592294.2015.1061174","volume":"10","author":"AS Gabriel","year":"2015","unstructured":"Gabriel AS, Lafta FM, Schwalbey EC, Nakjang S, Cockell SJ, Iliasova A, et al. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics (Taylor and Francis Inc). 2015;10:717\u201326. https:\/\/doi.org\/10.1080\/15592294.2015.1061174.","journal-title":"Epigenetics (Taylor and Francis Inc.)"},{"key":"4516_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00401-019-02020-0","volume":"138","author":"T Sharma","year":"2019","unstructured":"Sharma T, Schwalbe EC, Williamson D, Sill M, Hovestadt V, Mynarek M, et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathol (Springer Verlag). 2019;138:309\u201326. https:\/\/doi.org\/10.1007\/s00401-019-02020-0.","journal-title":"Acta Neuropathol (Springer Verlag)"},{"key":"4516_CR14","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1038\/sj.onc.1208568","volume":"24","author":"J Mazieres","year":"2005","unstructured":"Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, et al. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1. Oncogene (Nature Publishing Group). 2005;24:5396\u2013400. https:\/\/doi.org\/10.1038\/sj.onc.1208568.","journal-title":"Oncogene (Nature Publishing Group)"},{"key":"4516_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/b978-0-12-380866-0.60002-2","volume":"70","author":"M Kulis","year":"2010","unstructured":"Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27\u201356. https:\/\/doi.org\/10.1016\/b978-0-12-380866-0.60002-2.","journal-title":"Adv Genet"},{"key":"4516_CR16","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1038\/s41388-021-01923-1","volume":"40","author":"EC Schwalbe","year":"2021","unstructured":"Schwalbe EC, Lalchungnunga H, Lafta F, Barrow TM, Strathdee G. Integration of genome-level data to allow identification of subtype-specific vulnerability genes as novel therapeutic targets. Oncogene (Nature Publishing Group). 2021;40:5213\u201323. https:\/\/doi.org\/10.1038\/s41388-021-01923-1.","journal-title":"Oncogene (Nature Publishing Group)"},{"key":"4516_CR17","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.3390\/POLYM17212901","volume":"17","author":"L Abdulsalam","year":"2025","unstructured":"Abdulsalam L, Abubakar S, Permatasari I, Lawal AA, Uddin S, Ullah S, et al. Advanced biocompatible and biodegradable polymers: a review of functionalization, smart systems, and sustainable applications. Polymers (Basel) (Multidisciplinary Digital Publishing Institute (MDPI)). 2025;17:2901. https:\/\/doi.org\/10.3390\/POLYM17212901.","journal-title":"Polymers (Basel) (Multidisciplinary Digital Publishing Institute (MDPI))"},{"key":"4516_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.CELL.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell Cell Press. 2018;175:313\u201326. https:\/\/doi.org\/10.1016\/J.CELL.2018.09.035.","journal-title":"Cell Cell Press"},{"key":"4516_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/S41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol Springer Nature. 2020;17:807\u201321. https:\/\/doi.org\/10.1038\/S41423-020-0488-6.","journal-title":"Cell Mol Immunol Springer Nature"},{"key":"4516_CR20","first-page":"6537","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS. Next-generation immunotherapy advancing clinical applications in cancer treatment. J Clin Med (Multidisciplinary Digital Publishing Institute). 2024;13:6537.","journal-title":"J Clin Med (Multidisciplinary Digital Publishing Institute)"},{"key":"4516_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1053\/J.GASTRO.2023.04.029","volume":"165","author":"L Guo","year":"2023","unstructured":"Guo L, Wang Y, Yang W, Wang C, Guo T, Yang J, et al. Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis. Gastroenterology (WB Saunders). 2023;165:414-428.e7. https:\/\/doi.org\/10.1053\/J.GASTRO.2023.04.029.","journal-title":"Gastroenterology (W.B. Saunders)"},{"key":"4516_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB, Cercek A, Cho M, et al. Treatment of metastatic colorectal cancer: ASCO Guideline. J Clin Oncol (Lippincott Williams and Wilkins). 2023;41:678\u2013700. https:\/\/doi.org\/10.1200\/JCO.22.01690.","journal-title":"J Clin Oncol (Lippincott Williams and Wilkins)"},{"key":"4516_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(24)00600-4","volume":"26","author":"H Sung","year":"2025","unstructured":"Sung H, Siegel RL, Laversanne M, Jiang C, Morgan E, Zahwe M, et al. Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data. Lancet Oncol Elsevier Ltd. 2025;26:51\u201363. https:\/\/doi.org\/10.1016\/S1470-2045(24)00600-4.","journal-title":"Lancet Oncol Elsevier Ltd"},{"key":"4516_CR24","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.3390\/CANCERS17172804","volume":"17","author":"LF Leite","year":"2025","unstructured":"Leite LF, Noronha MM, de Menezes JSA, da Concei\u00e7\u00e3o LD, Almeida LFC, Cappellaro AP, et al. Anti-EGFR therapy in metastatic colorectal cancer: identifying, tracking, and overcoming resistance. Cancers (Basel) (Multidisciplinary Digital Publishing Institute (MDPI)). 2025;17:2804. https:\/\/doi.org\/10.3390\/CANCERS17172804.","journal-title":"Cancers (Basel) (Multidisciplinary Digital Publishing Institute (MDPI))"},{"key":"4516_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/CAAC.21772","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin Wiley. 2023;73:233\u201354. https:\/\/doi.org\/10.3322\/CAAC.21772.","journal-title":"CA Cancer J Clin Wiley"},{"key":"4516_CR26","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1038\/sj.onc.1201831","volume":"16","author":"Q Li","year":"1998","unstructured":"Li Q, Jedlicka A, Ahuja N, Gibbons MC, Baylin SB, Burger PC, et al. Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene (Nature Publishing Group). 1998;16:3197\u2013202. https:\/\/doi.org\/10.1038\/sj.onc.1201831.","journal-title":"Oncogene (Nature Publishing Group)"},{"key":"4516_CR27","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.4155\/fmc-2018-0227","volume":"10","author":"S Gao","year":"2018","unstructured":"Gao S, Lai L. Synthetic lethality in drug development: the dawn is coming. Future Med Chem (Future Medicine Ltd). 2018;10:2129\u201332. https:\/\/doi.org\/10.4155\/fmc-2018-0227.","journal-title":"Future Med Chem (Future Medicine Ltd)"},{"key":"4516_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (Wiley). 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin (Wiley)"},{"key":"4516_CR29","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/ng.2293","volume":"44","author":"MG Dunlop","year":"2012","unstructured":"Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, et al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet. 2012;44:770\u20136. https:\/\/doi.org\/10.1038\/ng.2293.","journal-title":"Nat Genet"},{"key":"4516_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1747326","author":"GH Yu","year":"2022","unstructured":"Yu GH, Li SF, Wei R, Jiang Z. Diabetes and colorectal cancer risk: clinical and therapeutic implications. J Diabetes Res (Wiley Online Library). 2022. https:\/\/doi.org\/10.1155\/2022\/1747326.","journal-title":"J Diabetes Res (Wiley Online Library)"},{"key":"4516_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2559.2009.03392.x","volume":"56","author":"G Poulogiannis","year":"2010","unstructured":"Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology. 2010;56:167\u201379. https:\/\/doi.org\/10.1111\/j.1365-2559.2009.03392.x.","journal-title":"Histopathology"},{"key":"4516_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/S00428-024-03746-3","volume":"484","author":"PD Dunne","year":"2024","unstructured":"Dunne PD, Arends MJ. Molecular pathological classification of colorectal cancer\u2014an update. Virchows Archiv (Springer). 2024;484:273\u201385. https:\/\/doi.org\/10.1007\/S00428-024-03746-3.","journal-title":"Virchows Archiv (Springer)"},{"key":"4516_CR33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/j.1440-1746.2012.07200.x","volume":"27","author":"S Al-Sohaily","year":"2012","unstructured":"Al-Sohaily S, Biankin A, Leong R, Kohonen-Corish M, Warusavitarne J. Molecular pathways in colorectal cancer. J Gastroenterol Hepatol (Blackwell Publishing). 2012;27:1423\u201331. https:\/\/doi.org\/10.1111\/j.1440-1746.2012.07200.x.","journal-title":"J Gastroenterol Hepatol (Blackwell Publishing)"},{"key":"4516_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/J.IMMUNI.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity Cell Press. 2020;52:17\u201335. https:\/\/doi.org\/10.1016\/J.IMMUNI.2019.12.011.","journal-title":"Immunity Cell Press"},{"key":"4516_CR35","doi-asserted-by":"publisher","first-page":"1067849","DOI":"10.3389\/FONC.2023.1067849\/TEXT","volume":"13","author":"P Pan","year":"2023","unstructured":"Pan P, Li J, Wang B, Tan X, Yin H, Han Y, et al. Molecular characterization of colorectal adenoma and colorectal cancer via integrated genomic transcriptomic analysis. Front Oncol (Frontiers Media SA). 2023;13:1067849. https:\/\/doi.org\/10.3389\/FONC.2023.1067849\/TEXT.","journal-title":"Front Oncol (Frontiers Media SA)"},{"key":"4516_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41586-024-08133-1","volume":"636","author":"Z Lu","year":"2024","unstructured":"Lu Z, Mo S, Xie D, Zhai X, Deng S, Zhou K, et al. Polyclonal-to-monoclonal transition in colorectal precancerous evolution. Nature (Nature Publishing Group). 2024;636:233\u201340. https:\/\/doi.org\/10.1038\/s41586-024-08133-1.","journal-title":"Nature (Nature Publishing Group)"},{"key":"4516_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399401003623","volume":"3","author":"IC Teller","year":"2001","unstructured":"Teller IC, Beaulieu JF. Interactions between laminin and epithelial cells in intestinal health and disease. Expert Rev Mol Med. 2001;3:1\u201318. https:\/\/doi.org\/10.1017\/S1462399401003623.","journal-title":"Expert Rev Mol Med"},{"key":"4516_CR38","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","volume":"3","author":"AB Schrock","year":"2017","unstructured":"Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, et al. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol (American Medical Association). 2017;3:1546\u201353. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1051.","journal-title":"JAMA Oncol (American Medical Association)"},{"key":"4516_CR39","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.6004\/JNCCN.2019.0043","volume":"17","author":"AB Benson","year":"2019","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Small bowel adenocarcinoma, version 1.2020. J Natl Compr Canc Netw (Harborside Press). 2019;17:1109\u201333. https:\/\/doi.org\/10.6004\/JNCCN.2019.0043.","journal-title":"J Natl Compr Canc Netw (Harborside Press)"},{"key":"4516_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEO.2025.101180","volume":"66","author":"R Ishikawa","year":"2025","unstructured":"Ishikawa R, Yamada H, Saitsu H, Miyazaki R, Takahashi J, Takinami R, et al. Immunohistochemical and molecular evolutionary features of jejunoileal adenocarcinoma unveiled through comparative analysis with colorectal adenocarcinoma. Neoplasia (Elsevier). 2025;66:101180. https:\/\/doi.org\/10.1016\/J.NEO.2025.101180.","journal-title":"Neoplasia (Elsevier)"},{"key":"4516_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4251\/wjgo.v14.i2.413","volume":"14","author":"D Khosla","year":"2022","unstructured":"Khosla D, Dey T, Madan R, Gupta R, Goyal S, Kumar N, et al. Small bowel adenocarcinoma: an overview. World J Gastrointest Oncol (Baishideng Publishing Group Inc). 2022;14:413\u201322. https:\/\/doi.org\/10.4251\/wjgo.v14.i2.413.","journal-title":"World J Gastrointest Oncol. (Baishideng Publishing Group Inc)"},{"key":"4516_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/J.EJCA.2023.02.016","volume":"186","author":"DT Le","year":"2023","unstructured":"Le DT, Diaz LA, Kim TW, Van Cutsem E, Geva R, J\u00e4ger D, et al. Pembrolizumab for previously treated, microsatellite instability\u2013high\/mismatch repair\u2013deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer (Pergamon). 2023;186:185\u201395. https:\/\/doi.org\/10.1016\/J.EJCA.2023.02.016.","journal-title":"Eur J Cancer (Pergamon)"},{"key":"4516_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-024-01578-X","author":"X Chong","year":"2024","unstructured":"Chong X, Madeti Y, Cai J, Li W, Cong L, Lu J, et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol (BioMed Central Ltd). 2024. https:\/\/doi.org\/10.1186\/S13045-024-01578-X.","journal-title":"J Hematol Oncol (BioMed Central Ltd)"},{"key":"4516_CR44","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/S41571-025-01015-Z","volume":"22","author":"M Ambrosini","year":"2025","unstructured":"Ambrosini M, Manca P, Nasca V, Sciortino C, Ghelardi F, Seligmann JF, et al. Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers. Nat Rev Clin Oncol (Springer Nature). 2025;22:385\u2013407. https:\/\/doi.org\/10.1038\/S41571-025-01015-Z.","journal-title":"Nat Rev Clin Oncol (Springer Nature)"},{"key":"4516_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/GCC.23015;WGROUP:STRING:PUBLICATION","volume":"61","author":"MC Olave","year":"2022","unstructured":"Olave MC, Graham RP. Mismatch repair deficiency: The what, how and why it is important. Genes Chromosomes Cancer (John Wiley and Sons Inc). 2022;61:314\u201321. https:\/\/doi.org\/10.1002\/GCC.23015;WGROUP:STRING:PUBLICATION.","journal-title":"Genes Chromosomes Cancer (John Wiley and Sons Inc)."},{"key":"4516_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/J.ANNONC.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Annal Oncol (Elsevier). 2022;33:929\u201338. https:\/\/doi.org\/10.1016\/J.ANNONC.2022.05.519.","journal-title":"Annal Oncol (Elsevier)"},{"key":"4516_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/J.YGYNO.2022.12.008","volume":"170","author":"C Mitric","year":"2023","unstructured":"Mitric C, Salman L, Abrahamyan L, Kim SR, Pechlivanoglou P, Chan KKW, et al. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol (Academic Press). 2023;170:133\u201342. https:\/\/doi.org\/10.1016\/J.YGYNO.2022.12.008.","journal-title":"Gynecol Oncol (Academic Press)"},{"key":"4516_CR48","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/ENCYCLOPEDIA2030106","volume":"2","author":"A Prisco","year":"2022","unstructured":"Prisco A, Barretta R, Sch\u00f6niger S, R\u00fcschoff J. Mismatch repair deficiency and microsatellite instability. Encyclopedia 2022 (Multidisciplinary Digital Publishing Institute). 2022;2:1559\u201376. https:\/\/doi.org\/10.3390\/ENCYCLOPEDIA2030106.","journal-title":"Encyclopedia 2022 (Multidisciplinary Digital Publishing Institute)"},{"key":"4516_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115233","author":"K Venetis","year":"2025","unstructured":"Venetis K, Frascarelli C, Bielo LB, Cursano G, Adorisio R, Ivanova M, et al. Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: a comprehensive cBioPortal study on prevalence and prognostic impact. Eur J Cancer (Elsevier Ltd). 2025. https:\/\/doi.org\/10.1016\/j.ejca.2025.115233.","journal-title":"Eur J Cancer (Elsevier Ltd)"},{"key":"4516_CR50","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/S41379-022-01109-4","volume":"35","author":"C Wang","year":"2022","unstructured":"Wang C, Zhang L, Vakiani E, Shia J. Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both? Mod Pathol (Elsevier). 2022;35:1515\u201328. https:\/\/doi.org\/10.1038\/S41379-022-01109-4.","journal-title":"Mod Pathol (Elsevier)"},{"key":"4516_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/S13258-024-01614-7","volume":"47","author":"Y Heo","year":"2025","unstructured":"Heo Y, Kim WJ, Cho YJ, Jung JW, Kim NS, Choi IY. Advances in cancer genomics and precision oncology. Genes Genom (Genetics Society of Korea). 2025;47:399\u2013416. https:\/\/doi.org\/10.1007\/S13258-024-01614-7.","journal-title":"Genes Genom (Genetics Society of Korea)"},{"key":"4516_CR52","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/JAMAONCOL.2024.3651","volume":"10","author":"CA O\u2019Connor","year":"2024","unstructured":"O\u2019Connor CA, Harrold E, Lin D, Walch H, Gazzo A, Ranganathan M, et al. Lynch syndrome and somatic mismatch repair variants in pancreas cancer. JAMA Oncol (American Medical Association). 2024;10:1511\u20138. https:\/\/doi.org\/10.1001\/JAMAONCOL.2024.3651.","journal-title":"JAMA Oncol (American Medical Association)"},{"key":"4516_CR53","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.16.299925","author":"J Ziegler","year":"2020","unstructured":"Ziegler J, Hechtman JF, Ptashkin R, Jayakumaran G, Middha S, Chavan SS, et al. MiMSI - a deep multiple instance learning framework improves microsatellite instability detection from tumor next-generation sequencing. Nat Commun. 2020. https:\/\/doi.org\/10.1101\/2020.09.16.299925.","journal-title":"Nat Commun"},{"key":"4516_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/S12022-024-09836-X","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O, Boucher A, Schrader KA, Abdel-Rahman O, Bahig H, Ho C, et al. Consensus statement: recommendations on actionable biomarker testing for thyroid cancer management. Endocr Pathol Springer. 2024;35:293\u2013308. https:\/\/doi.org\/10.1007\/S12022-024-09836-X.","journal-title":"Endocr Pathol Springer"},{"key":"4516_CR55","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/IJMS23020830","volume":"23","author":"JY Cho","year":"2022","unstructured":"Cho JY, Nski Pawe\u0142 K, Asiadek S, Ma\u0142gorzata M. CpG island methylator phenotype\u2014a hope for the future or a road to nowhere? Int J Mol Sci (Multidisciplinary Digital Publishing Institute). 2022;23:830. https:\/\/doi.org\/10.3390\/IJMS23020830.","journal-title":"Int J Mol Sci (Multidisciplinary Digital Publishing Institute)"},{"key":"4516_CR56","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/S41580-019-0159-6","volume":"20","author":"MVC Greenberg","year":"2019","unstructured":"Greenberg MVC, Bourc\u2019his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol (Nature Publishing Group). 2019;20:590\u2013607. https:\/\/doi.org\/10.1038\/S41580-019-0159-6.","journal-title":"Nat Rev Mol Cell Biol (Nature Publishing Group)"},{"key":"4516_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4254862","author":"J Wang","year":"2022","unstructured":"Wang J, Deng Z, Lang X, Jiang J, Xie K, Lu S, et al. Meta-analysis of the prognostic and predictive role of the CpG island methylator phenotype in colorectal cancer. Dis Markers (John Wiley & Sons Ltd). 2022. https:\/\/doi.org\/10.1155\/2022\/4254862.","journal-title":"Dis Markers (John Wiley & Sons Ltd)"},{"key":"4516_CR58","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/IJNRD.S42097","volume":"7","author":"LS Schmidt","year":"2014","unstructured":"Schmidt LS, Linehan WM. Hereditary leiomyomatosis and renal cell carcinoma. Int J Nephrol Renovasc Dis (Dove Medical Press Ltd). 2014;7:253\u201360. https:\/\/doi.org\/10.2147\/IJNRD.S42097.","journal-title":"Int J Nephrol Renovasc Dis (Dove Medical Press Ltd)"},{"key":"4516_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0278108","volume":"17","author":"CJ Ricketts","year":"2022","unstructured":"Ricketts CJ, Killian JK, Vocke CD, Wang Y, Merino MJ, Meltzer PS, et al. Kidney tumors associated with germline mutations of FH and SDHB show a CpG island methylator phenotype (CIMP). PLoS One (Public Library of Science). 2022;17:e0278108. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0278108.","journal-title":"PLoS One (Public Library of Science)."},{"key":"4516_CR60","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1073\/pnas.051633798","volume":"98","author":"V Launonen","year":"2001","unstructured":"Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA. 2001;98:3387\u201392. https:\/\/doi.org\/10.1073\/pnas.051633798.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4516_CR61","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","volume":"177","author":"RL Grubb","year":"2007","unstructured":"Grubb RL, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177:2074\u201380. https:\/\/doi.org\/10.1016\/j.juro.2007.01.155.","journal-title":"J Urol"},{"key":"4516_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/BIB\/BBAB610","author":"J Yates","year":"2022","unstructured":"Yates J, Boeva V. Deciphering the etiology and role in oncogenic transformation of the CpG island methylator phenotype: a pan-cancer analysis. Brief Bioinform (Oxford Academic). 2022. https:\/\/doi.org\/10.1093\/BIB\/BBAB610.","journal-title":"Brief Bioinform (Oxford Academic)"},{"key":"4516_CR63","doi-asserted-by":"publisher","first-page":"1008301","DOI":"10.3389\/FENDO.2022.1008301\/PDF","volume":"13","author":"P Gu","year":"2022","unstructured":"Gu P, Zeng Y, Ma W, Zhang W, Liu Y, Guo F, et al. Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma. Front Endocrinol (Lausanne) (Frontiers Media SA). 2022;13:1008301. https:\/\/doi.org\/10.3389\/FENDO.2022.1008301\/PDF.","journal-title":"Front Endocrinol (Lausanne) (Frontiers Media SA)"},{"key":"4516_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/J.CYTO.2025.156957","volume":"191","author":"S Pandey","year":"2025","unstructured":"Pandey S, Anshu T, Maharana KC, Sinha S. Molecular insights into diabetic wound healing: focus on Wnt\/\u03b2-catenin and MAPK\/ERK signaling pathways. Cytokine (Academic Press). 2025;191:156957. https:\/\/doi.org\/10.1016\/J.CYTO.2025.156957.","journal-title":"Cytokine (Academic Press)"},{"key":"4516_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald BT, Tamai K, He X. Wnt\/\u03b2-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17:9\u201326. https:\/\/doi.org\/10.1016\/j.devcel.2009.06.016.","journal-title":"Dev Cell"},{"key":"4516_CR66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41580-024-00823-y","volume":"26","author":"MM Maurice","year":"2025","unstructured":"Maurice MM, Angers S. Mechanistic insights into Wnt\u2013\u03b2-catenin pathway activation and signal transduction. Nat Rev Mol Cell Biol (Nature Publishing Group). 2025;26:371\u201388. https:\/\/doi.org\/10.1038\/s41580-024-00823-y.","journal-title":"Nat Rev Mol Cell Biol (Nature Publishing Group)"},{"key":"4516_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduction Targeted Ther (Nature Publishing Group). 2022;7:1. https:\/\/doi.org\/10.1038\/s41392-021-00762-6.","journal-title":"Signal Transduction Targeted Ther (Nature Publishing Group)"},{"key":"4516_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/S13045-024-01563-4","author":"P Song","year":"2024","unstructured":"Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y, et al. Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy. J Hematol Oncol (BioMed Central). 2024. https:\/\/doi.org\/10.1186\/S13045-024-01563-4.","journal-title":"J Hematol Oncol (BioMed Central)"},{"key":"4516_CR69","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1093\/BRAIN\/AWAC236","volume":"145","author":"Q Wang","year":"2022","unstructured":"Wang Q, Huang X, Su Y, Yin G, Wang S, Yu B, et al. Activation of Wnt\/\u03b2-catenin pathway mitigates blood\u2013brain barrier dysfunction in Alzheimer\u2019s disease. Brain (Oxford Academic). 2022;145:4474\u201388. https:\/\/doi.org\/10.1093\/BRAIN\/AWAC236.","journal-title":"Brain (Oxford Academic)"},{"key":"4516_CR70","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/IJMS23052810","volume":"23","author":"M Roche","year":"2022","unstructured":"Roche M, Vall\u00e9e A. Neuroinflammation in Schizophrenia: The Key Role of the WNT\/\u03b2-Catenin Pathway. Int J Mol Sci (Multidisciplinary Digital Publishing Institute). 2022;23:2810. https:\/\/doi.org\/10.3390\/IJMS23052810.","journal-title":"Int J Mol Sci (Multidisciplinary Digital Publishing Institute)"},{"key":"4516_CR71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/S12943-025-02363-1","volume":"24","author":"X Wu","year":"2025","unstructured":"Wu X, Que H, Li Q, Wei X. Wnt\/\u03b2-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy. Mol Cancer (BioMed Central). 2025;24:171. https:\/\/doi.org\/10.1186\/S12943-025-02363-1.","journal-title":"Mol Cancer (BioMed Central)."},{"key":"4516_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBRC.2024.150348","volume":"729","author":"C Samant","year":"2024","unstructured":"Samant C, Kale R, Pai KSR, Nandakumar K, Bhonde M. Role of Wnt\/\u03b2-catenin pathway in cancer drug resistance: insights into molecular aspects of major solid tumors. Biochem Biophys Res Commun (Academic Press). 2024;729:150348. https:\/\/doi.org\/10.1016\/J.BBRC.2024.150348.","journal-title":"Biochem Biophys Res Commun (Academic Press)"},{"key":"4516_CR73","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/S11658-022-00390-0","volume":"27","author":"P Liu","year":"2022","unstructured":"Liu P, Zu F, Chen H, Yin X, Tan X. Exosomal DNAJB11 promotes the development of pancreatic cancer by modulating the EGFR\/MAPK pathway. Cell Mol Biol Lett (BioMed Central). 2022;27:87. https:\/\/doi.org\/10.1186\/S11658-022-00390-0.","journal-title":"Cell Mol Biol Lett (BioMed Central)"},{"key":"4516_CR74","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3724\/ABBS.2023251","volume":"56","author":"Y Xie","year":"2023","unstructured":"Xie Y, Chen Z, Li S, Yan M, He W, Li L, et al. A network pharmacology- and transcriptomics-based investigation reveals an inhibitory role of \u03b2-sitosterol in glioma via the EGFR\/MAPK signaling pathway: Inhibitory role of \u03b2-sitosterol in glioma via EGFR\/MAPK pathway. Acta Biochim Biophys Sin (Shanghai). 2023;56:223. https:\/\/doi.org\/10.3724\/ABBS.2023251.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"4516_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/CTM2.847","volume":"12","author":"N Liang","year":"2022","unstructured":"Liang N, Bing Z, Wang Y, Liu X, Guo C, Cao L, et al. Clinical implications of EGFR-associated MAPK\/ERK pathway in multiple primary lung cancer. Clin Transl Med (John Wiley & Sons Ltd). 2022;12:e847. https:\/\/doi.org\/10.1002\/CTM2.847.","journal-title":"Clin Transl Med (John Wiley & Sons Ltd)"},{"key":"4516_CR76","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nature14969","volume":"526","author":"A Bertotti","year":"2015","unstructured":"Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature (Nature Publishing Group). 2015;526:263\u20137. https:\/\/doi.org\/10.1038\/nature14969.","journal-title":"Nature (Nature Publishing Group)"},{"key":"4516_CR77","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/s1470-2045(16)00150-9","volume":"17","author":"A Sartore-Bianchi","year":"2016","unstructured":"Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol (Lancet Publishing Group). 2016;17:738\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)00150-9.","journal-title":"Lancet Oncol (Lancet Publishing Group)"},{"key":"4516_CR78","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/nejmoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med (NEJM\/MMS). 2004;350:2335\u201342. https:\/\/doi.org\/10.1056\/nejmoa032691.","journal-title":"N Engl J Med (NEJM\/MMS)"},{"key":"4516_CR79","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328\u201335. https:\/\/doi.org\/10.1016\/j.bbrc.2005.05.132.","journal-title":"Biochem Biophys Res Commun"},{"key":"4516_CR80","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1038\/s41467-025-59588-3","volume":"16","author":"X Qu","year":"2025","unstructured":"Qu X, Hamidi H, Johnson RM, Sokol ES, Lin E, Eng C, et al. Ligand-activated EGFR\/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer. Nat Commun (Nature Publishing Group). 2025;16:4332. https:\/\/doi.org\/10.1038\/s41467-025-59588-3.","journal-title":"Nat Commun (Nature Publishing Group)"},{"key":"4516_CR81","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1158\/2159-8290.cd-15-1283","volume":"6","author":"M Russo","year":"2016","unstructured":"Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, et al. Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer. Cancer Discov (American Association for Cancer Research Inc). 2016;6:147\u201353. https:\/\/doi.org\/10.1158\/2159-8290.cd-15-1283.","journal-title":"Cancer Discov (American Association for Cancer Research Inc)"},{"key":"4516_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2022.860588\/FULL","volume":"13","author":"XY Yu","year":"2022","unstructured":"Yu XY, Sun Q, Zhang YM, Zou L, Zhao YY. TGF-\u03b2\/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Front Pharmacol (Frontiers Media SA). 2022;13:860588. https:\/\/doi.org\/10.3389\/FPHAR.2022.860588\/FULL.","journal-title":"Front Pharmacol (Frontiers Media SA)"},{"key":"4516_CR83","doi-asserted-by":"publisher","first-page":"1649179","DOI":"10.3389\/FONC.2025.1649179\/FULL","volume":"15","author":"F Chen","year":"2025","unstructured":"Chen F, Lyu L, Xing C, Chen Y, Hu S, Wang M, et al. The pivotal role of TGF-\u03b2\/Smad pathway in fibrosis pathogenesis and treatment. Front Oncol (Frontiers Media SA). 2025;15:1649179. https:\/\/doi.org\/10.3389\/FONC.2025.1649179\/FULL.","journal-title":"Front Oncol (Frontiers Media SA)"},{"key":"4516_CR84","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.7150\/IJBS.89568","volume":"20","author":"X Xin","year":"2024","unstructured":"Xin X, Cheng X, Zeng F, Xu Q, Hou L. The role of TGF-\u03b2\/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis. Int J Biol Sci (Ivyspring International Publisher). 2024;20:1436. https:\/\/doi.org\/10.7150\/IJBS.89568.","journal-title":"Int J Biol Sci (Ivyspring International Publisher)"},{"key":"4516_CR85","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3892\/MMR.2024.13267\/HTML","volume":"30","author":"J Li","year":"2024","unstructured":"Li J, Zou Y, Kantapan J, Su H, Wang L, Dechsupa N. TGF-\u03b2\/Smad signaling in chronic kidney disease: exploring post-translational regulatory perspectives (Review). Mol Med Rep (Spandidos Publications). 2024;30:143. https:\/\/doi.org\/10.3892\/MMR.2024.13267\/HTML.","journal-title":"Mol Med Rep (Spandidos Publications)"},{"key":"4516_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHYMED.2025.157496","volume":"148","author":"CH Jiang","year":"2025","unstructured":"Jiang CH, Zhang SJ, Li P, Miao H, Zhao YY. Natural products targeting TGF-\u03b2\/Smad signaling in renal fibrosis: multiomics-based novel molecular mechanisms and therapeutic strategies. Phytomedicine (Urban & Fischer). 2025;148:157496. https:\/\/doi.org\/10.1016\/J.PHYMED.2025.157496.","journal-title":"Phytomedicine (Urban & Fischer)"},{"key":"4516_CR87","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/JCP.30917","volume":"238","author":"L Wang","year":"2023","unstructured":"Wang L, Yu KC, Hou YQ, Guo M, Yao F, Chen ZX. Gut microbiome in tumorigenesis and therapy of colorectal cancer. J Cell Physiol (John Wiley and Sons Inc). 2023;238:94\u2013108. https:\/\/doi.org\/10.1002\/JCP.30917.","journal-title":"J Cell Physiol (John Wiley and Sons Inc)"},{"key":"4516_CR88","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41388-022-02569-3","volume":"42","author":"F Shi","year":"2022","unstructured":"Shi F, Liu G, Lin Y, Guo CL, Han J, Chu ESH, et al. Altered gut microbiome composition by appendectomy contributes to colorectal cancer. Oncogene (Nature Publishing Group). 2022;42:530\u201340. https:\/\/doi.org\/10.1038\/s41388-022-02569-3.","journal-title":"Oncogene (Nature Publishing Group)"},{"key":"4516_CR89","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/CANCERS15061913","volume":"15","author":"S Singh","year":"2023","unstructured":"Singh S, Sharma P, Sarma DK, Kumawat M, Tiwari R, Verma V, et al. Implication of obesity and gut microbiome dysbiosis in the etiology of colorectal cancer. Cancers (Multidisciplinary Digital Publishing Institute). 2023;15:1913. https:\/\/doi.org\/10.3390\/CANCERS15061913.","journal-title":"Cancers (Multidisciplinary Digital Publishing Institute)"},{"key":"4516_CR90","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/JNCI\/DJAB106","volume":"114","author":"ST Hoorn","year":"2022","unstructured":"Hoorn ST, De Back TR, Sommeijer DW, Vermeulen L. Clinical value of consensus molecular subtypes in colorectal cancer a systematic review and meta-analysis. J Natl Cancer Inst (Oxford Academic). 2022;114:503\u201316. https:\/\/doi.org\/10.1093\/JNCI\/DJAB106.","journal-title":"J Natl Cancer Inst (Oxford Academic)"},{"key":"4516_CR91","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-23-3964","volume":"30","author":"S Mouillet-Richard","year":"2024","unstructured":"Mouillet-Richard S, Cazelles A, Sroussi M, Gallois C, Taieb J, Laurent-Puig P. Clinical challenges of consensus molecular subtype CMS4 colon cancer in the era of precision medicine. Clin Cancer Res (American Association for Cancer Research Inc). 2024;30:2351\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3964.","journal-title":"Clin Cancer Res (American Association for Cancer Research Inc)"},{"key":"4516_CR92","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/S12254-023-00893-2","volume":"16","author":"P Noack","year":"2023","unstructured":"Noack P, Langer R, Noack P, Langer R. Molecular pathology of colorectal cancer. MEMO - Mag Eur Med Oncol (Springer). 2023;16:116\u201321. https:\/\/doi.org\/10.1007\/S12254-023-00893-2.","journal-title":"MEMO - Mag Eur Med Oncol (Springer)"},{"key":"4516_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRP.2023.154632","volume":"248","author":"A Kamrani","year":"2023","unstructured":"Kamrani A, Hosseinzadeh R, Shomali N, Heris JA, Shahabi P, Mohammadinasab R, et al. New immunotherapeutic approaches for cancer treatment. Pathol Res Pract (Urban & Fischer). 2023;248:154632. https:\/\/doi.org\/10.1016\/J.PRP.2023.154632.","journal-title":"Pathol Res Pract (Urban & Fischer)"},{"key":"4516_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/S12935-023-03158-4","author":"B Sun","year":"2023","unstructured":"Sun B, Xun Z, Zhang N, Liu K, Chen X, Zhao H. Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade. Cancer Cell Int (BioMed Central Ltd). 2023. https:\/\/doi.org\/10.1186\/S12935-023-03158-4.","journal-title":"Cancer Cell Int (BioMed Central Ltd)"},{"key":"4516_CR95","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1039\/D5BM01176K","volume":"13","author":"RGA Mohamed","year":"2025","unstructured":"Mohamed RGA, Ali SM, Ahmed IS, Rawas-Qalaji M, Hussain Z. Next-generation nanocarriers for colorectal cancer passive, active, and stimuli-responsive strategies for precision therapy. Biomater Sci (Royal Society of Chemistry). 2025;13:5626\u201364. https:\/\/doi.org\/10.1039\/D5BM01176K.","journal-title":"Biomater Sci (Royal Society of Chemistry)"},{"key":"4516_CR96","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1615\/CRITREVONCOG.V30.I1.110","volume":"30","author":"R Kumari","year":"2025","unstructured":"Kumari R, Ghava D, Rathod R, Panda AK, Kumar S, Behera SK. Molecular dynamics of adenomatous polyposis coli (APC) protein and its inhibitors: a special insight to colorectal cancer. Crit Rev Oncog (Begell House Inc). 2025;30:91\u2013105. https:\/\/doi.org\/10.1615\/CRITREVONCOG.V30.I1.110.","journal-title":"Crit Rev Oncog (Begell House Inc.)"},{"key":"4516_CR97","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12916-021-02070-w","volume":"19","author":"S Ramagopalan","year":"2021","unstructured":"Ramagopalan S, Leahy TP, Ray J, Wilkinson S, Sammon C, Subbiah V. The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. BMC Med (BioMed Central Ltd). 2021;19:209. https:\/\/doi.org\/10.1186\/s12916-021-02070-w.","journal-title":"BMC Med (BioMed Central Ltd)"},{"key":"4516_CR98","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12916-021-02213-z","volume":"20","author":"J M\u0105czy\u0144ska","year":"2022","unstructured":"M\u0105czy\u0144ska J, Raes F, Da Pieve C, Turnock S, Boult JKR, Hoebart J, et al. Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy. BMC Med (BioMed Central Ltd). 2022;20:16. https:\/\/doi.org\/10.1186\/s12916-021-02213-z.","journal-title":"BMC Med (BioMed Central Ltd)"},{"key":"4516_CR99","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/S12916-022-02287-3","volume":"20","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Li M. Targeted therapies for cancer. BMC Med (BioMed Central). 2022;20:90. https:\/\/doi.org\/10.1186\/S12916-022-02287-3.","journal-title":"BMC Med (BioMed Central)"},{"key":"4516_CR100","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1073\/PNAS.0710370104","volume":"104","author":"J Bean","year":"2007","unstructured":"Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932\u20137. https:\/\/doi.org\/10.1073\/PNAS.0710370104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4516_CR101","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","volume":"33","author":"CK Lee","year":"2015","unstructured":"Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol (American Society of Clinical Oncology). 2015;33:1958\u201365. https:\/\/doi.org\/10.1200\/JCO.2014.58.1736.","journal-title":"J Clin Oncol (American Society of Clinical Oncology)"},{"key":"4516_CR102","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJW279","author":"CK Lee","year":"2017","unstructured":"Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, et al. Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. J Natl Cancer Inst (Oxford University Press). 2017. https:\/\/doi.org\/10.1093\/JNCI\/DJW279.","journal-title":"J Natl Cancer Inst. (Oxford University Press)"},{"key":"4516_CR103","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.3390\/IJMS241713618","volume":"24","author":"HY Choi","year":"2023","unstructured":"Choi HY, Chang J-E, Choi HY, Chang JE. Targeted therapy for cancers from ongoing clinical trials to FDA-approved drugs. Int J Mol Sci (Multidisciplinary Digital Publishing Institute). 2023;24:13618. https:\/\/doi.org\/10.3390\/IJMS241713618.","journal-title":"Int J Mol Sci (Multidisciplinary Digital Publishing Institute)"},{"key":"4516_CR104","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/S40005-022-00594-8","volume":"52","author":"K Rhew","year":"2022","unstructured":"Rhew K, Chae YJ, Chang JE. Progress and recent trends in photodynamic therapy with nanoparticles. J Pharm Investig Springer. 2022;52:587\u201399. https:\/\/doi.org\/10.1007\/S40005-022-00594-8.","journal-title":"J Pharm Investig Springer"},{"key":"4516_CR105","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases\u2014elimination, equilibrium, and escape. Curr Opin Immunol. 2014;27:16\u201325. https:\/\/doi.org\/10.1016\/j.coi.2014.01.004.","journal-title":"Curr Opin Immunol"},{"key":"4516_CR106","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1093\/jnci\/djn389","volume":"100","author":"A Jemal","year":"1975","unstructured":"Jemal A, Thun MJ, Ries LAG, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975\u20132005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 1975;100:1672\u201394. https:\/\/doi.org\/10.1093\/jnci\/djn389.","journal-title":"J Natl Cancer Inst"},{"key":"4516_CR107","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1056\/nejmp1510079","volume":"373","author":"A Ribas","year":"2015","unstructured":"Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med (NEJM\/MMS). 2015;373:1490\u20132. https:\/\/doi.org\/10.1056\/nejmp1510079.","journal-title":"N Engl J Med (NEJM\/MMS)"},{"key":"4516_CR108","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"1979","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 1979;331:1565\u201370. https:\/\/doi.org\/10.1126\/science.1203486.","journal-title":"Science"},{"key":"4516_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/JCM9124038","author":"A Dulskas","year":"2020","unstructured":"Dulskas A, Gaizauskas V, Kildusiene I, Samalavicius NE, Smailyte G. Improvement of survival over time for colorectal cancer patients a population-based study. J Clin Med (Multidisciplinary Digital Publishing Institute (MDPI)). 2020. https:\/\/doi.org\/10.3390\/JCM9124038.","journal-title":"J Clin Med (Multidisciplinary Digital Publishing Institute (MDPI))"},{"key":"4516_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCONREL.2026.114839","volume":"394","author":"J Cordeiro","year":"2026","unstructured":"Cordeiro J, Macela C, Kleiner R, Vaskovich-Koubi D, Moura LIF, Satchi-Fainaro R, et al. Harnessing the power of microbiome, nanotechnology, and immunity against cancer. J Control Release (Elsevier). 2026;394:114839. https:\/\/doi.org\/10.1016\/J.JCONREL.2026.114839.","journal-title":"J Control Release (Elsevier)"},{"key":"4516_CR111","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1080\/00914037.2021.1960344","volume":"71","author":"CI Idumah","year":"2022","unstructured":"Idumah CI, Ezika AC. Recent advancements in hybridized polymer nano-biocomposites for tissue engineering. Int J Polym Mater Polym Biomater (Taylor and Francis Ltd). 2022;71:1262\u201376. https:\/\/doi.org\/10.1080\/00914037.2021.1960344.","journal-title":"Int J Polym Mater Polym Biomater (Taylor and Francis Ltd)"},{"key":"4516_CR112","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1021\/ACSABM.3C00549","volume":"6","author":"R Karmakar","year":"2023","unstructured":"Karmakar R, Dey S, Alam A, Khandelwal M, Pati F, Rengan AK. Attributes of nanomaterials and nanotopographies for improved bone tissue engineering and regeneration. ACS Appl Bio Mater (American Chemical Society). 2023;6:4020\u201341. https:\/\/doi.org\/10.1021\/ACSABM.3C00549.","journal-title":"ACS Appl Bio Mater (American Chemical Society)"},{"key":"4516_CR113","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.2147\/IJN.S298936","volume":"16","author":"NAA Halim","year":"2021","unstructured":"Halim NAA, Hussein MZ, Kandar MK. Nanomaterials-upconverted hydroxyapatite for bone tissue engineering and a platform for drug delivery. Int J Nanomed (Dove Medical Press Ltd). 2021;16:6477\u201396. https:\/\/doi.org\/10.2147\/IJN.S298936.","journal-title":"Int J Nanomed (Dove Medical Press Ltd)"},{"key":"4516_CR114","doi-asserted-by":"publisher","first-page":"19951","DOI":"10.1021\/ACSAMI.3C00655","volume":"15","author":"D Cheng","year":"2023","unstructured":"Cheng D, Ding R, Jin X, Lu Y, Bao W, Zhao Y, et al. strontium ion-functionalized nano-hydroxyapatite\/chitosan composite microspheres promote osteogenesis and angiogenesis for bone regeneration. ACS Appl Mater Interfaces (American Chemical Society). 2023;15:19951\u201365. https:\/\/doi.org\/10.1021\/ACSAMI.3C00655.","journal-title":"ACS Appl Mater Interfaces (American Chemical Society)"},{"key":"4516_CR115","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/S42114-024-00888-5","volume":"7","author":"H Wang","year":"2024","unstructured":"Wang H, Yusufu Y, Wang L, Gan J, Zhang M, Gu J, et al. Meso-reconstructed silk fibroin\/iron oxide nanoparticle composites dominated by silk I structures through unidirectional nanopore dehydration for potential application in bone regeneration. Adv Compos Hybrid Mater (Springer). 2024;7:84. https:\/\/doi.org\/10.1007\/S42114-024-00888-5.","journal-title":"Adv Compos Hybrid Mater (Springer)"},{"key":"4516_CR116","doi-asserted-by":"publisher","first-page":"34064","DOI":"10.1038\/s41598-025-14440-y","volume":"15","author":"F Ijaz","year":"2025","unstructured":"Ijaz F, Nasir B, Rashid SA, Naseem F, Jalil A, Riaz A, et al. Colistin adorned topical nanoemulsion gel formulation for enhanced anti-microbial activity. Sci Rep (Nature Publishing Group). 2025;15:34064. https:\/\/doi.org\/10.1038\/s41598-025-14440-y.","journal-title":"Sci Rep (Nature Publishing Group)"},{"key":"4516_CR117","doi-asserted-by":"publisher","DOI":"10.1080\/17435889.2025.2574384","author":"BJ Dutta","year":"2025","unstructured":"Dutta BJ, Patil VS, Gaikwad VL, Singh S. 2025 Intranasal administration of thermoresponsive pterostilbene loaded nanoemulgel confers neuroprotection in a rat model of ischemic stroke. Nanomedicine (Taylor & Francis). 2025. https:\/\/doi.org\/10.1080\/17435889.2025.2574384.","journal-title":"Nanomedicine (Taylor & Francis)"},{"key":"4516_CR118","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/S12951-024-02580-8","volume":"22","author":"W Zhang","year":"2024","unstructured":"Zhang W, Hou Y, Yin S, Miao Q, Lee K, Zhou X, et al. Advanced gene nanocarriers\/scaffolds in nonviral-mediated delivery system for tissue regeneration and repair. J Nanobiotechnol (BioMed Central). 2024;22:376. https:\/\/doi.org\/10.1186\/S12951-024-02580-8.","journal-title":"J Nanobiotechnol (BioMed Central)"},{"key":"4516_CR119","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3390\/CANCERS15051395","volume":"15","author":"SM Ruff","year":"2023","unstructured":"Ruff SM, Pawlik TM. A review of translational research for targeted therapy for metastatic colorectal cancer. Cancers (Multidisciplinary Digital Publishing Institute). 2023;15:1395. https:\/\/doi.org\/10.3390\/CANCERS15051395.","journal-title":"Cancers (Multidisciplinary Digital Publishing Institute)"},{"key":"4516_CR120","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/CANCERS17172810","volume":"17","author":"SA Khelwatty","year":"2025","unstructured":"Khelwatty SA, Puvanenthiran S, Seddon AM, Bagwan I, Essapen S, Modjtahedi H. Advancements in targeted therapies for colorectal cancer: overcoming challenges and exploring future directions. Cancers (Multidisciplinary Digital Publishing Institute). 2025;17:2810. https:\/\/doi.org\/10.3390\/CANCERS17172810.","journal-title":"Cancers (Multidisciplinary Digital Publishing Institute)"},{"key":"4516_CR121","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/J.HEALTHPOL.2022.10.007","volume":"126","author":"L Aguilera-Cobos","year":"2022","unstructured":"Aguilera-Cobos L, Rosario-Lozano MP, Ponce-Polo A, Blasco-Amaro JA, Epstein D. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: umbrella review. Health Policy (New York) (Elsevier). 2022;126:1248\u201355. https:\/\/doi.org\/10.1016\/J.HEALTHPOL.2022.10.007.","journal-title":"Health Policy (New York) (Elsevier)"},{"key":"4516_CR122","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/S41416-020-01089-9","volume":"124","author":"D Rossini","year":"2021","unstructured":"Rossini D, Lonardi S, Antoniotti C, Santini D, Tomasello G, Ermacora P, et al. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. Br J Cancer (Springer Nature). 2021;124:183\u201390. https:\/\/doi.org\/10.1038\/S41416-020-01089-9.","journal-title":"Br J Cancer (Springer Nature)"},{"key":"4516_CR123","doi-asserted-by":"publisher","first-page":"S298","DOI":"10.14309\/01.AJG.0001031052.12609.ED","volume":"119","author":"H Carr","year":"2024","unstructured":"Carr H, Reub N, Hughes BR, Lebduska E, Macke L, Francis P. S421 Lost in translation: deciphering the barriers to colorectal cancer screening among Spanish Speaking Patients. Am J Gastroenterol (Ovid Technologies (Wolters Kluwer Health)). 2024;119:S298\u20139. https:\/\/doi.org\/10.14309\/01.AJG.0001031052.12609.ED.","journal-title":"Am J Gastroenterol (Ovid Technologies (Wolters Kluwer Health))"},{"key":"4516_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/J.CTRV.2022.102466","volume":"110","author":"KK Iyer","year":"2022","unstructured":"Iyer KK, van Erp NP, Tauriello DVF, Verheul HMW, Poel D. Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer. Cancer Treat Rev (W B Saunders). 2022;110:102466. https:\/\/doi.org\/10.1016\/J.CTRV.2022.102466.","journal-title":"Cancer Treat Rev (W. B. Saunders)"},{"key":"4516_CR125","doi-asserted-by":"publisher","DOI":"10.1080\/00914037.2021.1925277","author":"AAG El-Shahawy","year":"2021","unstructured":"El-Shahawy AAG, Elnagar N, Zohery M, Sabry M, Elhafeez A, El-Dek SI. Smart nanocarrier-based chitosan @silica coated carbon nanotubes composite for breast cancer treatment approach. Int J Polym Mater Polym Biomater. 2021. https:\/\/doi.org\/10.1080\/00914037.2021.1925277.","journal-title":"Int J Polym Mater Polym Biomater"},{"key":"4516_CR126","doi-asserted-by":"publisher","first-page":"14447","DOI":"10.1038\/s41598-020-71071-1","volume":"10","author":"M Chen","year":"2020","unstructured":"Chen M, Hu J, Wang L, Li Y, Zhu C, Chen C, et al. Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy. Sci Rep (Nature Publishing Group). 2020;10:14447. https:\/\/doi.org\/10.1038\/s41598-020-71071-1.","journal-title":"Sci Rep (Nature Publishing Group)"},{"key":"4516_CR127","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/J.JHEP.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol (Elsevier BV). 2022;77:1598\u2013606. https:\/\/doi.org\/10.1016\/J.JHEP.2022.08.021.","journal-title":"J Hepatol (Elsevier B.V.)"},{"key":"4516_CR128","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMRA1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. Longo DL, editor. New Engl J Med. 2019;380:1450\u201362. https:\/\/doi.org\/10.1056\/NEJMRA1713263.","journal-title":"New Engl J Med"},{"key":"4516_CR129","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.21037\/QIMS-22-763\/COIF","volume":"13","author":"C Zeng","year":"2023","unstructured":"Zeng C, Guo B, Zhang S, Zhou Z, Cai Q, Hou L, et al. Age-related changes in lumbar bone mineral density measured using quantitative computed tomography in healthy female cynomolgus monkeys. Quant Imaging Med Surg (AME Publishing Company). 2023;13:2038\u201352. https:\/\/doi.org\/10.21037\/QIMS-22-763\/COIF.","journal-title":"Quant Imaging Med Surg (AME Publishing Company)"},{"key":"4516_CR130","doi-asserted-by":"publisher","first-page":"1594217","DOI":"10.3389\/FSURG.2025.1594217\/FULL","volume":"12","author":"P Korovessis","year":"2025","unstructured":"Korovessis P, Syrimpeis V, Korovesis A, Dimakopoulos G. Incidence of new osteoporotic adjacent vertebral body fractures. A comparison between conservative treatment and vertebral body augmentation (vertebroplasty, kyphoplasty): a systematic review and meta-analysis. Front Surg (Frontiers Media SA). 2025;12:1594217. https:\/\/doi.org\/10.3389\/FSURG.2025.1594217\/FULL.","journal-title":"Front Surg (Frontiers Media SA)"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04516-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:02:11Z","timestamp":1785182531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04516-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":130,"alternative-id":["4516"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04516-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review based on previously published literature and does not contain any original studies involving human participants or animals performed by any of the authors. Therefore, ethical approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval (Research Involving Human Participants and\/or Animals)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was not required for this study because it does not involve human participants or identifiable personal data.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}